It was established that the major users of the SGLT2-inhibitors belong to middle-aged to elderly individuals due to the medications’ efficiency in managing diseases that are the result of diabetes (Huang et al., 2021). This evidence concerns the gene SLC5A2 and diabetes mellitus.